Although ours and other studies show that BORT efficiently inhibits survival and induces apoptosis in BCR/ABL cells, a pilot study [15] reported minimal efficacy and considerable toxicity in CML patients receiving BORT therapy. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.